Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer.

Immune Check Point inhibitors (ICIs) have demonstrated efficacy in advanced stage solid tumors including non-small cell lung cancer (NSCLC), CTLA4, programmed cell death-1 (PD-1) and PD-1 ligand 1 (PD-L1) inhibitors being the most studied drugs.

[1]  Jose Belderbos,et al.  Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Weichselbaum,et al.  Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. , 2014, The Journal of clinical investigation.

[3]  Tarek Mekhail,et al.  Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[4]  N. Kawashima,et al.  Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 Antibody , 2009, Clinical Cancer Research.

[5]  Nicolas André,et al.  Mathematical Modeling of Cancer Immunotherapy and Its Synergy with Radiotherapy. , 2016, Cancer research.

[6]  W. Curran,et al.  Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. , 2015, The Lancet. Oncology.

[7]  Ping Zhang,et al.  Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. , 2008, Molecular immunology.

[8]  A. Mansfield,et al.  B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8+ T cells , 2016, Scientific Reports.

[9]  R. Stewart,et al.  PD-L1 blockade for cancer treatment: MEDI4736. , 2015, Seminars in oncology.

[10]  D. Planchard,et al.  A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study. , 2016, Clinical lung cancer.

[11]  S. Gettinger,et al.  Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. , 2017, The Lancet. Oncology.

[12]  M. Socinski,et al.  Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. , 2014, The Lancet. Oncology.

[13]  K. Steele,et al.  Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. , 2016, The Lancet. Oncology.